

---

# Economics and Preventing Hospital-acquired Infection

Nicholas Graves\*

The economics of preventing hospital-acquired infections is most often described in general terms. The underlying concepts and mechanisms are rarely made explicit but should be understood for research and policy-making. We define the key economic concepts and specify an illustrative model that uses hypothetical data to identify how two related questions might be addressed: 1) how much should be invested for infection control, and 2) what are the most appropriate infection-control programs? We aim to make explicit the economics of preventing hospital-acquired infections.

---

Approximately 1 in 10 hospitalized patients will acquire an infection after admission, which results in substantial economic cost (1). The primary cost is that patients with hospital-acquired infections have their stay prolonged, during which time they occupy scarce bed-days and require additional diagnostic and therapeutic interventions (2). Estimates of the cost of these infections, in 2002 prices, suggest that the annual economic costs are \$6.7 billion per year in the United States (3)<sup>1</sup> and £1.06 billion (approximately US \$1.7 billion) in the United Kingdom (4).

The economic rationale for preventing hospital-acquired infections has been discussed (5,6) and can be summarized as follows: hospital-acquired infections take up scarce health sector resources by prolonging patients' hospital stay; effective infection-control strategies release these resources for alternative uses. If these resources have a value in an alternative use, then the infection control programs can be credited with generating cost savings; these infection control programs are costly themselves, so the expense of infection control should be compared to the savings.

For many hospital infections, the costs of prevention are likely to be lower than the value of the resources released (4,7,8), even when costs "are estimated liberally and the benefits presented conservatively" (9). Under these circumstances, infection control should be pursued, since more

stands to be gained than lost (5). We attempt to make explicit the concepts on which these arguments rely and, in particular, concentrate on providing a framework for answering two questions: how much in total should we invest in prevention for any given infection-control situation, and how should this investment be allocated among competing infection-control strategies? Our aim is to make the economics of prevention explicit while using a minimum of technical language, algebra, and economics jargon.

## Concepts and Definitions

### Valuing Resources Attributable to Hospital-acquired Infection

Infection uses hospital resources. By preventing infection, these resources are saved. For some of these resources, the associated expenditures may be terminated, and the savings would be expressed in terms of cash-savings, for example saving on drugs, consumables, and nursing staff employed on a contract that can be terminated at short notice. However, expenditures associated with many resources are difficult to avoid in the short term, and conserved resources cannot be easily, or costlessly, exchanged for cash. A longer-term obligation to the resource may exist due to a contractual commitment, such as an employment contract with a staff member or a lease agreement for a diagnostic device, or a physical commitment, such as investment in buildings, capital equipment, and infrastructure.

These differences illustrate the differences between fixed and variable costs. While cash-savings from avoided variable costs are easy to quantify, the resources that represent fixed costs cannot be exchanged for cash in the short-term. Researchers have found that 84% (10) and 89% (4) of the costs of hospital care are fixed in the short term. Furthermore, expenditures made to acquire fixed resources, recorded by cost-accountants, may or may not

---

\*Centre for Health Research—Public Health (CHR—PH), Queensland University of Technology, Kelvin Grove, Brisbane, Australia

<sup>1</sup>Care should be taken in interpreting this estimate, as it was derived from data gathered in the mid-1970s (Study on the Efficacy of Nosocomial Infection Control—SENIC).




Figure 1. A model of investment in infection-control activities. Line A, cost and effectiveness of infection control; line B1, gross costs of infection and benefits of prevention; line B2, net costs of infection and benefits of infection control; line C, total costs; point X, incidence that minimizes total costs.

be an accurate assessment of their economic value. Because financial expenditures on fixed costs are unavoidable in the short-term, they are largely irrelevant to decision-making in the short-term. For economic analysis, we prefer to explore the value of the best alternative use of the resources that are fixed in the cost structure of the hospital. This value is the opportunity cost of the resource.

### Perspective for Economic Evaluation

Many have argued that the benefits of infection control are widespread. Treating infection represents an economic burden to the hospital, and prevention saves these costs (4,11–20); however, less is known about other benefits. One reason might be that hospital administrators, who hold the purse strings for infection control, are primarily interested in savings to their budgets and do not focus on other benefits that might arise for patients, informal caregivers, or other healthcare agencies (20). A broader perspective might include the monetary value of avoided illness and death from hospital infection. Attributing excess illness and death to hospital infection, however, is difficult, and accurately valuing these very real costs is fraught with problems. Still, when a narrow perspective is adopted, and costs and benefits other than those that fall directly on the hospital sector are excluded, economic analyses may underestimate the social benefits of infection-control programs.

### Incremental and Marginal Analyses

Incremental and marginal analyses are concerned with changes to “cost” and “benefit” in respect to the status quo (existing hospital expenditures and their outcomes) (21). If the existing budget for infection control is \$100,000 and a new infection-control program costs \$40,000, the total cost

of infection control will increase to \$140,000. The incremental cost of the new program is the change in total cost from \$100,000 to \$140,000, or \$40,000. If implementing this program avoids 50 bloodstream infections, then the incremental benefits are 50 avoided infections. Marginal analysis is similar but refers to a change of just one unit, say \$1 or one infection. Most infection-control programs would cause incremental changes, not pure marginal changes.

### Infection-Control Investment and Strategies

In the sections that follow, we adopt the perspective of a hospital administrator and only examine costs and savings to the hospital. We do not seek to determine a social value of the health benefits of avoiding hospital-acquired infection, so the estimate of the benefits of infection control is conservative. We also assume that all decisions are made within the short term; this is the time frame in which fixed costs cannot be changed. The model illustrated in Figure 1 uses hypothetical data to analyze the costs and benefits of prevention and provides answers to both questions: 1) how much to invest for infection control and 2) which are the most appropriate infection-control programs.

### How Much To Invest for Infection Control

The horizontal axis in Figure 1 represents an incidence of wound infections in 50,000 patients undergoing hip replacement. The vertical axis represents cost and potential savings. Line A summarizes the relationship between the cost and the effectiveness of infection control strategies. To achieve the low incidence of 0.01% requires an investment of resources in infection control valued at \$1.5 million. However, to reduce rates to only 5.00% requires a lesser investment of \$393,661. Line B1 represents the

gross costs of hospital infection, i.e., the gross savings that would result from prevention. These costs and potential savings increase with incidence. The primary cost of hospital infection is the loss of bed-days due to prolonged length of stay. Care must be taken in valuing these bed-days and other resources used for hospital infection (22). For economic analysis, consider what else could be done with the resources released by prevention. A hospital in which rates of infection are successfully reduced will have more bed-days available, so new patients can be admitted. The value of these new admissions to the hospital represents the gross costs of infection and, therefore, the potential gross savings from prevention. For example, if demand for hip replacement is such that patients, their insurers, or the public medical system is prepared to pay \$1,250 to the hospital for each additional case treated, then the opportunity cost of wound infection is the revenue that could be earned by treating extra cases with the bed-days used by hospital infection. In Appendix 1 (available online at: <http://www.cdc.gov/eid/vol10no4/02-0754.htm#app1>), we illustrate how to calculate these costs for an incidence of 10.00% and 5.00%, and these data are used to plot line B1 in Figure 1.

So far we have restricted our discussion of the cost and savings from prevention to changes in the use of bed-days. We should also consider the financial expenditures made by the hospital. The financial expenditures on resources that represent fixed costs are largely irrelevant, as they cannot be avoided in the short-term. However, fixed costs are certainly being used more productively.<sup>2</sup> More relevant are the variable or discretionary costs that change in response to a decrease in the incidence of hospital infection. First, patients who previously would have stayed for 15 days with a hospital infection now stay only 10 and will incur lower variable costs.<sup>3</sup> If the decrease in variable costs from reducing length of stay by 5 days is \$100 per patient, then line B1 in Figure 1 is too low an estimate of the costs of infection and the potential savings from prevention. However, variable costs will also increase as a result of the increase in patient turnover. At rates of zero infection, hospitals are treating 2,500 more patients than before, and this will cause an increase in variable costs. For example, the capacity to perform the surgery will have to be increased, requiring more surgeons, anesthetists, operating room nurses, and prostheses and other consumables. If the increase in variable cost is evaluated at \$750 per new admission, then this must be offset against the \$100 per patient reduction in variable costs and the \$1,250 increase in revenue per case. The result is the net costs of infection and net savings from prevention. In Appendix 2 (available online at: <http://www.cdc.gov/eid/vol10no4/02-754.htm#app2>), we illustrate how to calculate these costs for an incidence of

10.00% and 5.00%. This suggests that the gross cost of infection (the gross savings from prevention), marked by line B1, is incorrect. We indicate the correct values, the net cost of infection (the net savings from prevention), by line B2.

Line C in Figure 1 is the total cost to the healthcare system and is the sum of lines A and B2 for every incidence rate of hospital infection. For example, at an incidence of 9.00%, the net cost of infection is \$1,582,536 (Line B2), and the cost of prevention programs is \$132,088 (Line A). The sum of these at an incidence of 9.00% is \$1,714,624 (Line C).

The incidence of infection that minimizes total cost, indicated by Line C, is marked with an X in Figure 1, and achieving this incidence represents a rational objective for policy makers. To explore this point further, consult Appendix 3 (available online at: <http://www.cdc.gov/eid/vol10no4/02-0754.htm#app3>), which includes the values used to plot lines A, B2, and C between the incidence rates of 2.9% and 3.4%. We conclude that point X is a rational policy goal because, at this point, marginal savings exactly compensate the marginal investments in prevention. In contrast, investments that drive infection rates lower than point X are not adequately compensated. The data included in Appendix 3 show that the last infection we should prevent will cost \$17,810 in terms of infection-control activities and will release resources worth \$17,810.

The investment in prevention that achieves the rate indicated by point X is therefore the correct budget constraint for infection control. At point X, there is no net gain or loss, which signals the best achievable, or equilibrium, outcome.

### Determining Appropriate Infection-Control Programs

There are many different ways of preventing hospital infections and therefore many different ways of moving toward point X. Choices have to be made among the numerous competing infection-control programs available. To help make these choices, we apply the technique of incremental cost-effectiveness analysis (23), where the costs of the interventions are represented in monetary terms, and the benefits are measured in natural units common to all interventions under consideration. For this example, the benefits of the infection-control programs are

<sup>2</sup>At rates of 10% the fixed costs of the organization were used to treat 50,000 patients, but at zero rates of infection, 52,500 patients were treated with the same volume of fixed costs; this represents an improvement in efficiency. See Appendix 1, available online at <http://www.cdc.gov/ncidod/EID/vol10no4/02-0754.htm#app1>

<sup>3</sup>Reductions might be in expenditures on antimicrobials to treat the infection, the equipment used to deliver therapy, and on resources used for wound care such as dressings, irrigations, and other consumables. Also, the workload of the nursing staff may be reduced, so expenditures on agency nurses might be reduced.

Table. Cost, effectiveness, and benefits of six competing infection-control strategies

Option	Incremental cost of prevention	Incremental benefit <sup>a</sup>	Effect <sup>b</sup>
Option 6	\$299,611	1,942	4.00%
Option 3	\$523,487	1,205	2.50%
Option 2	\$643,487	3,346	6.80%
Option 5	\$812,457	3,448	7.10%
Option 1	\$874,512	1,059	2.20%
Option 4	\$892,931	3,960	8.00%

<sup>a</sup>Cases prevented.

<sup>b</sup>Reduction in incidence.

the number of cases of infection avoided. We should choose the infection-control programs that minimize the cost per infection avoided while remaining within the budget constraint identified by point X.

A useful first step is to identify a patient group and an infection to prevent. Keeping with the example of infection in hip replacement, the next step is to identify all reasonable strategies that might prevent this type of infection. In our example, we propose six strategies and assume that all available prevention strategies are represented by these six options. The cost, effectiveness, and benefits of each are illustrated in the Table, and these data are plotted in Figure 2. Options 1 to 6 compete with each other, and only the most appropriate will be used.

The status quo is an incidence of 10.00% for a population of 50,000 patients who receive a new hip in a given period. Option 6 is clearly preferable to options 1 to 5 because the cost of preventing one infection by this mode is only \$154, calculated by dividing the cost of option 6 by the benefit of option 6, both relative to the status quo. This is an incremental cost-effectiveness ratio (ICER). See Appendix 4 (available online at: <http://www.cdc.gov/eid/vol10no4/02-0754.htm#app4>) to clarify how to calculate

ICERs. In our example, the hospital should first invest \$299,611, moving from the origin to option 6.

Now, all other options (except option 6) are still available, and any further decisions must be evaluated with respect to option 6, the new status quo. Both option 1 and option 3 are less effective and more costly than the status quo (option 6) and so are excluded. Option 2 beats options 4 and 5; although all prevent further infections, option 2 does so at the lowest cost. The hospital should invest a further \$343,876, moving from option 6 to option 2. The status quo is now option 2, and only options 4 and 5 remain, with the final move being to option 4.

The question of which are the most appropriate infection-control programs has been answered. A policy represented by a line that joins the origin to the points marked option 6, option 2, and option 4 illustrates the most appropriate, most cost-effective, infection-control strategy.

We have pursued the most cost-effective pathway without considering point X, where total costs to the healthcare system are minimized. Consider the information included in Figure 3. This is a version of Figure 1 that includes the incremental costs and benefits of the six competing strategies described above. The status quo, at an incidence of 10%, and the moves to options 6, 2, and 4 that define the cost-effective pathway are marked. The figure shows that the hospital should not invest beyond the point defined by option 2. While a further move to option 4 is the lowest cost alternative for preventing further cases of infection, option 4 exceeds the budget constraint and ultimately increases costs to the healthcare system (line C).

**Discussion**

Many have considered the economics of preventing hospital-acquired infection. We argue, with the exception




Figure 2. A model of cost, effectiveness, and benefits of six competing infection-control strategies.




Figure 3. Six competing infection-control strategies imposed on the model of investment in infection-control activities.

of one study (24), the complexity of the economic issues has been neglected. In this article we attempt to make the economics explicit. We demonstrated how the concept of opportunity cost might be used to value the costs of hospital infection and therefore the savings from infection control programs. We argue that existing literature uses financial costs to represent the cost of infection, and this method may lead to erroneous conclusions. Financial costs are a monetized estimate value of health-services cost (25) and might not satisfy the definition of opportunity cost. We offer an explicit treatment of how variable costs change in response to infection control and highlight the difference between the gross and net costs of hospital infection. We also suggest that, as the perspective for the analysis broadens, the costs of infection and the potential benefits of infection control increase. This will affect the position of point X in our example and, therefore, affect infection control policy. Finally, we identify a budget constraint for infection control where the costs of prevention are compensated by simultaneous cost-savings and illustrate how incremental cost-effectiveness analysis might be used to identify the most efficient choices for infection control.

To build the model we propose requires data to plot lines B2 and A; obtaining these data will allow line C to be estimated and point X to be identified for any given hospital infection scenario. Plotting line B2 requires data on the incidence of hospital infection and the resulting opportunity costs. Although a complicated task, progress is being made with the specification of models (26,27), and establishing the true effect of hospital infection on length of stay and cost is now a more rigorous process. Deriving values of alternative uses of these bed-days represents further challenges. Due to the absence of a reliable market mechanism for health care, finding an accurate valuation for a marginal admission to a hospital is difficult

(28), as is finding the opportunity cost of bed-days. Further research in this area is required. Plotting line A requires that the cost and effectiveness of competing infection control strategies be understood. Although the number of economic evaluations that include an assessment of costs and benefits of infection-control strategies are limited (29), a broad and diverse literature exists on the effectiveness of many infection-control interventions. The quality of the evidence is likely to be variable, encompassing a range between correctly designed, randomized controlled trials and subjective, expert opinion. If the findings could be synthesized in a rigorous manner, uncertainty characterized, and summary estimates of the likely effectiveness derived, the costs of these strategies could be estimated separately and the data required to plot line A procured. With data to plot lines A and B2, line C, and point X can be estimated. Achieving this for the numerous patient groups and sites of hospital infection will be a major task, but the conceptual framework, expertise, and data are available for an explicit treatment of the economics of preventing hospital infection.

#### Acknowledgments

I am grateful to Douglas Scott II for his comments, Jennifer A. Roberts for her constant support, and an anonymous National Health and Medical Research Council reviewer for correcting some terms and definitions.

Dr. Graves is a senior research fellow in health economics with a joint appointment in the School of Public Health, Queensland University of Technology, and the Centre for Healthcare Related Infection Control and Surveillance, Princess Alexandra Hospital, Brisbane. His research interests include all aspects of the economics of hospital infection and other infectious diseases.

## References

1. Plowman RP, Graves N, Roberts JA. Hospital acquired infection. London: Office of Health Economics; 1997.
2. Haley R. Measuring the costs of nosocomial infections: methods for estimating economic burden on the hospital. *Am J Med* 1991;91:32S-8S.
3. Haley RW. Incidence and nature of endemic and epidemic nosocomial infections. In: Bennett JV, Brachman P, editors. *Hospital infections*. Boston: Little, Brown; 1985. p. 359-74.
4. Plowman RP, Graves N, Griffin MAS, Roberts JA, Swan AV, Cookson B, et al. The rate and cost of hospital-acquired infections occurring in patients admitted to selected specialties of a district general hospital in England and the national burden imposed. *J Hosp Infect* 2001;47:198-209.
5. Cohen DR. Economic issues in infection control. *J Hosp Infect* 1984;5:17-25.
6. Drummond M, Davies LF. Evaluation of the costs and benefits of reducing hospital infection. *J Hosp Infect* 1991;18(Suppl A):85-93.
7. Currie E, Maynard A. *The economics of hospital acquired infection*. 1st ed. York, UK: University of York; 1989.
8. Haley RW. Preliminary cost-benefit analysis of hospital infection control programs (The SENIC Project). In: Daschner F, editor. *Proven and unproven methods in hospital infection control*. Stuttgart: Gustav, Fisher and Verlag; 1978. p. 93-6.
9. Wenzel R. The economics of nosocomial infection. *J Hosp Infect* 1995;31:79-87.
10. Roberts RR, Frutos PW, Ciavarella GC, Gussow LM, Mensah EK, Kampe LM, et al. Distribution of fixed vs variable costs of hospital care. *JAMA* 1999;281:644-9.
11. Haley RW, Schaberg D, Crossley K, Von Allmen S, McGowan J. Extra charges and prolongation of stay attributable to nosocomial infections: a prospective inter-hospital comparison. *Am J Med* 1981;70:51-8.
12. Coello R, Glenister H, Fereres J, Bartlett C, Leigh D, Sedgwick J, et al. The cost of infection in surgical patients: a case control study. *J Hosp Infect* 1993;25:239-50.
13. Scheckler WE. Hospital costs of nosocomial infections: a prospective three month study in a community hospital. *Infection Control* 1980;1:150-2.
14. Li L, Wang S. A prospective study of nosocomial infections in cardiac surgery patients in China. *Am J Infect Control* 1990;18:365-70.
15. Kappstein I, Schulgen G, Fraedrich G, Schlosser V, Schumacher M, Daschner FD. Added hospital stay due to wound infections following cardiac surgery. *Thorac Cardiovasc Surg* 1992;40:148-51.
16. Pena C, Pujol M, Pallares R, Corbella X, Vidal T, Tortras N, et al. Estimation of costs attributable to nosocomial infection: prolongation of hospitalization and calculation of alternative costs. *Medicina Clinica* 1996;106:441-4.
17. Poulsen KB, Bremmelgaard A, Sorensen AI, Raahave D, Petersen JV. Estimated costs of postoperative wound infections. a case-control study of marginal hospital costs and social security costs. *Epidemiol Infect* 1994;113:283-95.
18. Kirkland K, Briggs J, Trivette S, Wilkinson W, Sexton D. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. *Infect Control Hosp Epidemiol* 1999;20:725-30.
19. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. excess length of stay, extra costs and attributable mortality. *JAMA* 1994;271:1598-601.
20. Haley RW. Cost-benefit analysis of infection control activities. In: Brachman P, Bennett J, editors. *Hospital infections*. Philadelphia: Lippincott-Raven; 1998. p. 249-67.
21. Torgerson DJ, Spencer A. Marginal costs and benefits. *BMJ* 1996;312:35-6.
22. Finkler SA. The distinction between costs and charges. *Ann Intern Med* 1982;96:102-9.
23. Robinson R. Cost-effectiveness analysis. *BMJ* 1993;307:793-5.
24. Persson U, Montgomery F, Carlsson A, Lindgren B, Ahnfelt L. How far prophylaxis against infection in total joint replacement offset its cost? *BMJ* 1988;296:99-102.
25. Kulcher F, Golan E. *Assigning values to life: comparing methods for valuing health risks*. Washington, DC: United States Department of Agriculture; 1999.
26. Fraser VJ. Starting to learn about the costs of nosocomial infections in the new millennium: where do we go from here? *Infect Control Hosp Epidemiol* 2002;23:174-6.
27. Hollenbeak CS, Murphy D, Dunagan WC, Fraser VJ. Nonrandom selection and the attributable cost of surgical-site infections. *Infect Control Hosp Epidemiol* 2002;23:177-82.
28. Scott RD, Soloman SL, McGowan JE. Applying economic principles to health care. *Emerg Infect Dis* 2001;7:282-5.
29. Stone WP, Larson E, Kawar LN. A systematic audit of economic evidence linking nosocomial infections and infection control interventions: 1990-2000. *Am J Infect Control* 2002;30:145-52.

---

Address for correspondence: Nicholas Graves, School of Public Health, Queensland University of Technology, Victoria Park Road, Kelvin Grove, QLD, 4059, Australia; fax: 61-7-3864-3369; email: n.graves@qut.edu.au

EMERGING INFECTIOUS DISEASES *online*

[www.cdc.gov/eid](http://www.cdc.gov/eid)

To receive tables of contents of new issues send an email to [listserv@cdc.gov](mailto:listserv@cdc.gov) with subscribe eid-toc in the body of your message.